All In Biotech

Drug Trial Radar · NCT04602754

Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.

National, Multicenter, Randomized, Double-blind, Triple-dummy, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.

Last checked: Nov 19, 2026Latest source record: Dec 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 228 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

228

Planned (sponsor's estimate)

Start

Dec 1, 2023

Primary completion

May 2026

Study completion Sep 2027

Sponsor

Lead sponsor
EMSIndustry
Sponsor type
Industry
First posted
Oct 26, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of Berlim 25/20 association in the treatment of type 2 diabetes mellitus and dyslipidemia.

Conditions

  • Dyslipidemia Associated With Type II Diabetes Mellitus

Interventions

  • BERLIM 25/20 ASSOCIATIONDrug

    Berlim 25/20 association coated tablet.

  • EMPAGLIFLOZIN PLACEBOOther

    Empagliflozin placebo coated tablet.

  • ROSUVASTATIN CALCIUM PLACEBOOther

    Rosuvastatin calcium placebo coated tablet.

  • EMPAGLIFLOZINDrug

    Empagliflozin 25 mg coated tablet.

  • ROSUVASTATIN CALCIUMDrug

    Rosuvastatin 20 mg coated tablet.

  • BERLIM 25/20 ASSOCIATION PLACEBOOther

    Berlim 25/20 association placebo coated tablet.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Reduction of glycated hemoglobin levels measured between the first visit and the last visit.Time frame: 120 days
  2. Percentual reduction of LDL-c levels measured between the first visit and the last visit.Time frame: 120 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Allergisa

    Campinas, São Paulo, Brazil · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.